Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SAMe for depression

This article was originally published in The Tan Sheet

Executive Summary

Augmentation of antidepressant therapy with S-adenosyl-L-methionine (SAMe) "warrants a placebo-controlled trial in resistant depression," authors of a Pharmavite-sponsored trial conclude in the Dec. 6 Journal of Clinical Psychopharmacology. Jonathan Alpert, MD/PhD, Massachusetts General Hospital, et al., administered 800 to 1,600 mg of SAMe to antidepressant partial and non-responders over a six-week period, recording a 50% response rate and a 43% rate of remission. A double-blind, placebo-controlled study at NIH to test SAMe as an adjunct antidepressant therapy also is being conducted by Alpert et al. A second NIH study will test SAMe against standard antidepressants and placebo...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel